Exact Sciences, a $876m developer of cancer screening and diagnostic test products to detect colorectal, prostate and other cancers, has acquired PreventionGenetics, a genetic testing laboratory. The deal complements Exact Sciences' advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing. PreventionGenetics is a CLIA-certified and CAP-accredited clinical DNA testing laboratory, providing more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline whole exome and whole genome sequencing tests. Deal value - $190m (50% in Exact Sciences' common stock and 50% in cash) on sales of $36m(5.2x) and EBITDA o $3m(63.3x).
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Diagnostics, COVID-19